2018, Number 1
<< Back Next >>
Acta Med 2018; 16 (1)
Comments about the paper Myelofibrosis
Hurtado MR, Azaola EP, Coronel AFO, Vargas VP
Language: Spanish
References: 9
Page: 92-93
PDF size: 102.35 Kb.
Text Extraction
No abstract.
REFERENCES
Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. Blood. 2017; 129 (6): 693-703.
Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017; 130 (17): 1889-1897.
Vargas-Viveros P, Hurtado-Monroy R, Candelaria-Hernández MG. Mejoría en la calidad de vida y respuesta sintomática en pacientes con mielofibrosis primaria, mielofibrosis post-policitemia vera y mielofibrosis post-trombocitemia esencial tratados con el inhibidor de JAK-1 y JAK-2 ruxolitinib. Med Int Mex. 2013; 29 (4): 363-69.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127 (20): 2391-2405.
Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016; 127 (20): 2361-2364.
Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017; 129 (6): 667-679.
Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017; 376 (22): 2168-2181.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011; 29 (4): 392-397.
Agarwald AM, Prchal JT. Anemia associated with marrow infiltration. En: Kaushansky K, Lichtman M, Beutler E, Kipps T, Prchal J, Seligsohn U. Williams hematology. 8th ed. New York: McGraw Hill; 2010: pp. 613-616.
Full text